GW PHARMACEUTICALS PLC's ticker is GWPH and the CUSIP is 36197T103. A total of 289 filers reported holding GW PHARMACEUTICALS PLC in Q1 2020. The put-call ratio across all filers is 1.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $4,883,000 | +15.2% | 22,517 | -38.7% | 0.01% | +7.7% |
| Q4 2020 | $4,240,000 | +42.7% | 36,747 | +20.3% | 0.01% | +30.0% |
| Q3 2020 | $2,972,000 | -5.2% | 30,534 | +19.5% | 0.01% | -16.7% |
| Q2 2020 | $3,135,000 | +37.9% | 25,551 | -1.6% | 0.01% | +9.1% |
| Q1 2020 | $2,273,000 | -18.0% | 25,963 | -2.1% | 0.01% | 0.0% |
| Q4 2019 | $2,771,000 | +1.0% | 26,507 | +11.1% | 0.01% | -8.3% |
| Q3 2019 | $2,744,000 | -29.7% | 23,861 | +5.4% | 0.01% | -29.4% |
| Q2 2019 | $3,903,000 | +15.3% | 22,644 | +12.7% | 0.02% | +6.2% |
| Q1 2019 | $3,386,000 | +61.6% | 20,091 | -6.6% | 0.02% | +45.5% |
| Q4 2018 | $2,095,000 | -36.5% | 21,518 | +12.6% | 0.01% | -31.2% |
| Q3 2018 | $3,300,000 | +52.6% | 19,106 | +23.3% | 0.02% | +45.5% |
| Q2 2018 | $2,163,000 | +85.0% | 15,500 | +49.3% | 0.01% | +83.3% |
| Q1 2018 | $1,169,000 | +26.4% | 10,383 | +48.2% | 0.01% | +20.0% |
| Q4 2017 | $925,000 | – | 7,007 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SCOPIA CAPITAL MANAGEMENT LP | 3,455,054 | $456,102,000 | 8.18% |
| Consonance Capital Management LP | 675,492 | $89,172,000 | 8.05% |
| Prisma Capital Partners LP | 33,000 | $4,356,000 | 4.11% |
| Broadfin Capital, LLC | 122,930 | $16,228,000 | 2.65% |
| Rock Springs Capital Management LP | 354,000 | $46,732,000 | 2.12% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 339,180 | $44,775,000 | 1.76% |
| GREAT POINT PARTNERS LLC | 75,000 | $9,901,000 | 1.69% |
| Atika Capital Management LLC | 31,000 | $4,092,000 | 1.58% |
| Sivik Global Healthcare LLC | 30,000 | $3,960,000 | 1.47% |
| Sio Capital Management, LLC | 19,000 | $2,508,000 | 1.41% |